CA2947781A1 - Antidiabetic tricyclic compounds - Google Patents

Antidiabetic tricyclic compounds Download PDF

Info

Publication number
CA2947781A1
CA2947781A1 CA2947781A CA2947781A CA2947781A1 CA 2947781 A1 CA2947781 A1 CA 2947781A1 CA 2947781 A CA2947781 A CA 2947781A CA 2947781 A CA2947781 A CA 2947781A CA 2947781 A1 CA2947781 A1 CA 2947781A1
Authority
CA
Canada
Prior art keywords
group
6alkyl
unsubstituted
substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2947781A
Other languages
English (en)
French (fr)
Inventor
Tesfaye BIFU
Purakkattle Biju
Timothy A. Blizzard
Zhengxia CHEN
Matthew J. Clements
Mingxiang Cui
Jessica L. Frie
William K. Hagmann
Bin Hu
Hubert Josien
Anilkumar G. Nair
Christopher W. Plummer
Cheng Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2947781A1 publication Critical patent/CA2947781A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/39—Unsaturated compounds containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2947781A 2014-05-22 2015-05-19 Antidiabetic tricyclic compounds Abandoned CA2947781A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2014/078104 WO2015176267A1 (en) 2014-05-22 2014-05-22 Antidiabetic tricyclic compounds
CNPCT/CN2014/078104 2014-05-22
PCT/CN2015/079262 WO2015176640A1 (en) 2014-05-22 2015-05-19 Antidiabetic tricyclic compounds

Publications (1)

Publication Number Publication Date
CA2947781A1 true CA2947781A1 (en) 2015-11-26

Family

ID=54553222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2947781A Abandoned CA2947781A1 (en) 2014-05-22 2015-05-19 Antidiabetic tricyclic compounds

Country Status (11)

Country Link
US (1) US10000454B2 (enExample)
EP (1) EP3145915B1 (enExample)
JP (1) JP2017516771A (enExample)
KR (1) KR20170005861A (enExample)
CN (1) CN106458913A (enExample)
AU (1) AU2015263620B2 (enExample)
CA (1) CA2947781A1 (enExample)
ES (1) ES3016636T3 (enExample)
MX (1) MX2016015182A (enExample)
RU (1) RU2016150413A (enExample)
WO (2) WO2015176267A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102435080B1 (ko) 2016-07-19 2022-08-22 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 축합 바이시클릭 헤테로사이클 유도체
CN106588673B (zh) * 2016-12-20 2018-06-26 金凯(辽宁)化工有限公司 一种2-甲基-5-氨基三氟甲苯的制备方法
AU2018331125A1 (en) 2017-09-12 2020-03-05 Jiangsu Hengrui Medicine Co., Ltd. Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
EP3709995A4 (en) 2017-11-16 2021-04-14 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP4227302A1 (en) 2018-02-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11963947B2 (en) * 2018-05-31 2024-04-23 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition and compound preparation comprising glucokinase activator and DPP-IV inhibitor, and preparation method and use thereof
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN116159052B (zh) * 2019-03-18 2025-04-11 深圳微芯生物科技股份有限公司 联合用药应用以及一种药用组合物及其应用
CN112574122B (zh) * 2019-09-27 2024-05-31 上海天慈国际药业有限公司 一种奥拉帕尼关键中间体的制备方法
CA3156985A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
JP7745559B2 (ja) 2020-02-28 2025-09-29 キャリーオペ，インク． Ｇｐｒ４０アゴニスト
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN114249724B (zh) * 2020-09-25 2023-05-26 鲁南制药集团股份有限公司 一种唑吡坦中间体的制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515482A (ja) 1997-03-07 2001-09-18 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規なベンズイミダゾールインヒビター
US6054587A (en) 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
CA2343027A1 (en) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
CA2415742A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
JP4181408B2 (ja) 2001-01-30 2008-11-12 メルク エンド カムパニー インコーポレーテッド 肥満、糖尿病及び脂質異常を治療するためのアシルスルファミド類
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
JP4340232B2 (ja) 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド 抗糖尿病活性を有するインドール類
BR0313825A (pt) 2002-08-29 2005-07-12 Merck & Co Inc Composto, composição farmacêutica, método para tratar de diabete mellitus tipo 2 em um mamìfero, e, uso de composto
CA2497901A1 (en) 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
EP1587535A4 (en) 2003-01-17 2010-02-24 Merck & Co Inc N-cyclohexylaminocarbonyl-benzenesulfonamide derivatives
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
US8008525B2 (en) 2003-11-26 2011-08-30 Takeda Pharmaceutical Company Limited Receptor function regulating agent
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
AU2005220728B2 (en) 2004-02-27 2009-08-06 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
JPWO2006038738A1 (ja) 2004-10-08 2008-05-15 武田薬品工業株式会社 受容体機能調節剤
AU2006211514A1 (en) 2005-01-28 2006-08-10 Merck & Co., Inc. Antidiabetic bicyclic compounds
CA2593858A1 (en) 2005-01-31 2006-08-10 Min Ge Antidiabetic bicyclic compounds
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
EP2001844A2 (en) 2006-03-14 2008-12-17 Amgen, Inc Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
JP5271895B2 (ja) * 2006-05-15 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション 抗糖尿病性の二環式化合物
PT2248812E (pt) 2006-06-27 2014-03-12 Takeda Pharmaceutical Compostos cíclicos fundidos como moduladores do receptor gpr40
US7714008B2 (en) 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
AU2007292816B2 (en) 2006-09-07 2011-11-17 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
AU2007314405A1 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2008054674A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
TW200838526A (en) * 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
AU2008241490B2 (en) 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
CA2691010A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
AU2008276568A1 (en) 2007-07-19 2009-01-22 Merck & Co., Inc. Beta carboline derivatives as antidiabetic compounds
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
CA2702047C (en) 2007-10-10 2012-04-17 Amgen Inc. Substituted biphenyl gpr40 modulators
EP2215068B1 (en) 2007-10-29 2012-06-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
WO2010045258A2 (en) 2008-10-15 2010-04-22 Amgen Inc. Spirocyclic gpr40 modulators
JP2012515781A (ja) 2009-01-23 2012-07-12 シェーリング コーポレイション 架橋および縮合複素環式抗糖尿病化合物
EP2389369A1 (en) 2009-01-23 2011-11-30 Schering Corporation Pentafluorosulpholane-containing antidiabetic compounds
WO2010085528A1 (en) 2009-01-23 2010-07-29 Schering Corporation Bridged and fused antidiabetic compounds
TW201040186A (en) 2009-02-05 2010-11-16 Schering Corp Phthalazine-containing antidiabetic compounds
EP2440541A1 (en) 2009-06-09 2012-04-18 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
CN102985362A (zh) 2010-07-08 2013-03-20 索尔维公司 LiPO2F2的制造
US20120302566A1 (en) 2010-12-01 2012-11-29 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
DK2797888T3 (en) * 2011-12-31 2016-09-19 Beigene Ltd Fused tricyclic compounds as RAF kinase inhibitors
GB2498976A (en) 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
WO2013122029A1 (ja) 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
EP2816023A4 (en) 2012-02-13 2015-09-09 Takeda Pharmaceutical AROMATIC RING CONNECTION
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
TWI692469B (zh) * 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds

Also Published As

Publication number Publication date
AU2015263620B2 (en) 2019-02-07
JP2017516771A (ja) 2017-06-22
AU2015263620A8 (en) 2017-02-02
EP3145915A1 (en) 2017-03-29
WO2015176267A1 (en) 2015-11-26
EP3145915A4 (en) 2017-11-01
AU2015263620A1 (en) 2016-10-20
RU2016150413A (ru) 2018-06-26
MX2016015182A (es) 2017-03-03
US10000454B2 (en) 2018-06-19
US20170081287A1 (en) 2017-03-23
ES3016636T3 (en) 2025-05-09
KR20170005861A (ko) 2017-01-16
CN106458913A (zh) 2017-02-22
WO2015176640A1 (en) 2015-11-26
RU2016150413A3 (enExample) 2018-11-16
EP3145915B1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
CA2947781A1 (en) Antidiabetic tricyclic compounds
EP3177282B1 (en) Antidiabetic bicyclic compounds
EP3177287B1 (en) Antidiabetic bicyclic compounds
EP3177614B1 (en) Fused bicyclic antidiabetic compounds
EP3177285A1 (en) [5,6]-fused bicyclic antidiabetic compounds
EA024293B1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ с-kit КИНАЗЫ
AU2018257203B2 (en) Novel tetrahydronaphthyl urea derivatives
TW202532063A (zh) 三環性螺化合物之用途
WO2017201683A1 (en) Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
WO2015095256A1 (en) Antidiabetic substituted heteroaryl compounds
WO2015046482A1 (ja) ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
US10336748B2 (en) Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
CN109071548A (zh) 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物
WO2016120850A9 (en) Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof
EP3383388A1 (en) Aryl acylsulfonamides as blt1 antagonists
JP2024543107A (ja) 疾患又は障害の治療のためのナフチリジノン誘導体
WO2018107415A1 (en) Hydroxy isoxazole compounds useful as gpr120 agonists
TW202535370A (zh) 作為nod樣受體蛋白3抑制劑之吲唑衍生物
WO2025067258A1 (zh) 哒嗪酮类化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
HK1240210B (zh) 酰胺类衍生物、其制备方法及其在医药上的用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123

FZDE Discontinued

Effective date: 20211123